Jonathan Wosen is a Biotech & Life Sciences Reporter at STAT News. He specializes in covering topics related to medicine, healthcare, and alternative medicine, with a strong focus on academia, biotech, and data, as well as the intersection of these fields with government and politics. Jonathan's work has been featured in prominent publications including The San Diego Union-Tribune, Los Angeles Times, and La Jolla Light.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
San Diego, United States (Local)
Not enough data
Jonathan Wosen's articles predominantly focus on the scientific and healthcare sectors, particularly biotech, medical research, drug development, pharmaceuticals, and genetic disorders. His coverage heavily involves citing data and government announcements.
When reaching out to Jonathan with pitches or expert commentary, consider providing insights backed by credible data or referencing recent relevant government announcements in the scientific and healthcare fields. Pitches that align with his focus on breakthroughs in biotech and drug development as well as advancements in medical research are likely to be well-received.
As his geographic focus is not specified but covers global topics within the industry of interest, it is important for sources to provide insights from a wide range of locations without being limited geographically.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jonathan Wosen, Tara Bannow, Bob Herman
By: Annalisa Merelli, Jonathan Wosen
The killing of Brian Thompson lays bare the rising threat level for health care executives.
By: Adam Feuerstein, Jonathan Wosen
By: Meghana Keshavan, Adam Feuerstein, Angus Chen, Jonathan Wosen
Biopharma leaders at companies developing blood cancer therapies say we shouldn't be afraid to use the four-letter word: cure.
By: Adam Feuerstein, Meghana Keshavan, Angus Chen, Jonathan Wosen
By: Jonathan Wosen, Matthew Herper
By: Jonathan Wosen, Matthew Herper
Ionis is expecting a FDA decision by Dec. 19 on approval of a drug designed to improve the body's ability to break down fats
By: Jonathan Wosen, Matthew Herper
By: Jonathan Wosen
Ionis won FDA approval for a drug for patients with a deadly genetic disease that impedes the body’s ability to break down fats
(833) 317-6278 
